



Cost-Effectiveness of Cerebrolysin[®] after Ischemic Stroke – A pharmaeconomic evaluation

Strilciuc et al., Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study. Healthcare 2023 11 (10), 1497.


- Costs-effective therapy
- Cost reduction in about 80%
- Optimal treatment options

Cerebrolysin[®]

**Reconnecting Neurons.
Empowering for Life.**

Importance of cost-effectiveness analysis for **Cerebrolysin**

- Help to identify the most efficient use of limited healthcare resources
- Introduction of new therapies providing the greatest value to patients and society
- Ensure to provide optimal care while maintaining financial sustainability
- Improving patient outcomes and reducing the burden on healthcare systems




Cost-effectiveness Plan



FAVORABLE **COST-EFFECTIVENESS** OF **CEREBROLYSIN** AGAINST PLACEBO

Cost-effectiveness Acceptability Curve



CEREBROLYSIN ADD-ON TREATMENT COST EFFECTIVE IN **ABOUT 80% OF CASES**



New cost-utility assessment for **Cerebrolysin** as a complementary treatment after stroke now available.



Using real-world data from a well designed clinical trial to assess the cost-effectiveness of **Cerebrolysin**.



Understanding the agent's cost-effectiveness profile is important, to inform decision-makers about the value of **Cerebrolysin** in the management of ischemic stroke.

STRONG ROBUSTNESS OF DATA SET

Three different methods* of ICER value calculation to guarantee the robustness of data




This ensures that there are no potential differences in preferences and risk attitudes which affect the overall cost-benefit analysis


*Standard gamble / Ordinal / Bayesian posterior mean



A treatment with **Cerebrolysin** is cost-effective in 80% of cases



Cerebrolysin mainly reduces event costs due to early remobilization and in addition, rehabilitation and nursing-home costs¹



Cerebrolysin add-on scheme has a beneficial impact on the quality of life of ischemic stroke patients



Findings are in line with the existing literature on this topic^{1,2}

CONCLUSION

The results indicate a favorable cost-effectiveness profile for Cerebrolysin as add-on treatment in moderate–severe acute ischemic stroke!

CEREBROLYSIN® DOSAGE FOR STROKE PATIENTS

Daily dosage

20 – 50 ml

Initiation of treatment

as soon as possible

Treatment Duration

10 – 21 days



Title: Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study.

Author: S. Strilciuc, et al.

Journal: Healthcare 2023; 11(10), 1497

URL: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218347/>

¹ Walter, E. et al., Cost-Effectiveness Of Combined Treatment With Alteplase (Rt-Pa) And Cerebrolysin In Acute Ischemic Hemispheric Stroke In Austria. Value in Health 2015; 18(7), A390.

² Kulikov, A. & Abdrashitova G., Cost-Effectiveness Analysis of Cerebrolysin In The Treatment of Patients With Acute Ischemic Stroke Moderate and Severe Degrees of Severity In The Russian Federation. Value in Health 2015; 18(7), A705.

Copyright © 2023 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria

ABBREVIATED PRESCRIBING INFORMATION – Cerebrolysin. Name of the medicinal product: Cerebrolysin – Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorization Holder: EVER Neuro Pharma GmbH, A-4866 Unterach Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.

EVER Pharma GmbH
Oberburgau 3
4866 Unterach
Austria

www.everpharma.com
www.cerebrolysin.com